Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 6/20 | 0.81 |
| ▸ | GAA | P10253 | 5/20 | 0.81 |
| ▸ | SI | P14410 | 5/20 | 0.81 |
| ▸ | MGAM2 | Q2M2H8 | 5/20 | 0.81 |
| ▸ | NUDT1 | P36639 | 4/20 | 0.81 |
| ▸ | FASN | P49327 | 4/20 | 0.81 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.81 |
| ▸ | IDH1 | O75874 | 4/20 | 0.81 |
| ▸ | PGAM1 | P18669 | 3/20 | 0.81 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.81 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.81 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.81 |
| ▸ | TTR | P02766 | 1/20 | 0.81 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.81 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.81 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.81 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.81 |
| ▸ | RELA | Q04206 | 3/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13081216 | 0.94 | MGAM (0.79) | MGAMGAASIMGAM2NUDT1 | |
| SCHEMBL3753526 | 0.90 | MGAM (1.00) | MGAMGAASIMGAM2NUDT1 | |
| SCHEMBL30634827 | 0.90 | MGAM (1.00) | MGAMGAASIMGAM2NUDT1 | |
| SCHEMBL29460081 | 0.90 | MGAM (1.00) | MGAMGAASIMGAM2NUDT1 | |
| SCHEMBL3416398 | 0.87 | MGAM (0.81) | MGAMGAASIMGAM2NUDT1 | |
| SCHEMBL12241934 | 0.87 | MGAM (0.81) | MGAMGAASIMGAM2NUDT1 | |
| SCHEMBL16260214 | 0.86 | MGAM (0.64) | MGAMGAASIMGAM2NUDT1 | |
| Mangostin SCHEMBL354735 | 0.84 | MGAM (1.00) | MGAMGAASIMGAM2NUDT1 | |
| Mangostin SCHEMBL29433195 | 0.84 | MGAM (1.00) | MGAMGAASIMGAM2NUDT1 | |
| Mangostin SCHEMBL29466055 | 0.84 | MGAM (1.00) | MGAMGAASIMGAM2NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036319-B2 | Polyvalent sting activating compositions and uses thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-16 | — | — | US | disclosed |
| US-20140349918-A1 | DERIVATIVES OF XANTHONE COMPOUNDS | SINGAPORE HEALTH SERVICES PTE LTD. (SG) | 2014-11-27 | — | — | US | disclosed |
| US-8461360-B2 | Process for producing γ -mangostin | LAILA NUTRACEUTICALS (US) | 2013-06-11 | — | — | US | disclosed |
| US-7981438-B2 | Use of α-mangostin as a mosquito larvicide | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-07-19 | — | — | US | disclosed |
| US-20080300300-A1 | Use of alpha-mangostin as a mosquito larvicide | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036319-B2 | Polyvalent sting activating compositions and uses thereof | STING1, CGAS, TLR7 | MGAM 3674/4885GAA 1162/4885SI 2347/4885 |
| US-20140349918-A1 | DERIVATIVES OF XANTHONE COMPOUNDS | XDH, XPA, SQLE | MGAM 1085/4885GAA 349/4885SI 2891/4885 |
| US-20080300300-A1 | Use of alpha-mangostin as a mosquito larvicide | MTX1, MTX2, L3MBTL1 | MGAM 492/4885GAA 2576/4885SI 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.